Bellevue Life Sciences Acquisition Corp. Warrant
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquire companies in the healthcare industry. The company was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp… Read more
Bellevue Life Sciences Acquisition Corp. Warrant (BLACW) - Total Liabilities
Latest total liabilities as of June 2024: $5.49 Million USD
Based on the latest financial reports, Bellevue Life Sciences Acquisition Corp. Warrant (BLACW) has total liabilities worth $5.49 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bellevue Life Sciences Acquisition Corp. Warrant - Total Liabilities Trend (2020–2023)
This chart illustrates how Bellevue Life Sciences Acquisition Corp. Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bellevue Life Sciences Acquisition Corp. Warrant Competitors by Total Liabilities
The table below lists competitors of Bellevue Life Sciences Acquisition Corp. Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EQUATORIAL RES
BE:PBU
|
Germany | €1.85 Million |
|
Fidelity European Values
LSE:FEV
|
UK | GBX2.62 Million |
|
Coro Energy PLC
LSE:CORO
|
UK | GBX2.59 Million |
|
EYANG HOLDINGS
BE:4EY
|
Germany | €1.35 Billion |
|
Fame Productions Inc
PINK:FMPR
|
USA | $710.70K |
|
Scage Future Warrants
NASDAQ:SCAGW
|
USA | $27.43 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Bellevue Life Sciences Acquisition Corp. Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bellevue Life Sciences Acquisition Corp. Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bellevue Life Sciences Acquisition Corp. Warrant (2020–2023)
The table below shows the annual total liabilities of Bellevue Life Sciences Acquisition Corp. Warrant from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $4.11 Million | +225.19% |
| 2022-12-31 | $1.26 Million | +78.64% |
| 2021-12-31 | $707.21K | +119.93% |
| 2020-12-31 | $321.56K | -- |